Register | Login
Intellectual Property Today
RFC Express - Document Management System
2013 Top Patent Firms
2013 Top Trademark Firms
Current Issue

Advertising Opportunities

Click Here

Email A Friend Back to Archived News

Key Patents Issued for ARCADô Instillate for the Prevention of Surgical Adhesions

Friday, May 04, 2007

Vancouver -- The University of British Columbia (UBC) and ARC Pharmaceuticals Inc. (ARC) today announced that key patents relating to ARC's lead product candidate, ARCAD™ Instillate, for the prevention and treatment of surgical adhesions, were recently issued or granted in several territories. The patents are assigned to UBC and ARC previously in-licensed these technologies through an exclusive worldwide license agreement with UBC.

USA Patent # 7,163,930, Australia Patent # 2002325113 and New Zealand Patent # 532015 were recently issued and China Patent # 02816693.0 was granted and will be registered in Hong Kong. These patents are in addition to the earlier issued USA Patent # 6,812,220 and a portfolio of related patent applications in additional territories. The patents relate to the use of fucans including fucoidan for the prevention and treatment of surgical adhesions and/or fibrous adhesions. Fucoidan is the key component of ARCAD™ Instillate.

"The issuance of these patents is an important step in continuing to strengthen ARC's patent position around ARCAD™ Instillate," stated Barbara Campbell, Associate Director for the University-Industry Liaison Office at UBC.

"ARC has demonstrated in several different preclinical models of surgical adhesions that the use of ARCAD™ Instillate resulted in a significant reduction in the number and severity of post-surgical adhesions," said Chris Springate, President and CEO of ARC.

About ARCAD™ technology

The key component of ARCAD™ Instillate is a fucan known as fucoidan. Fucoidan is a naturally occurring polysaccharide and is extracted from seaweed or brown marine algae. ARC has purified and incorporated fucoidan into the Company's proprietary lead product candidate, ARCAD™ Instillate, for the prevention of surgical adhesions. ARC has also commenced exploration of the use of the ARCAD™ technology in other disease indications and has formulated ARCAD™ as a gel and as a film.

About ARC Pharmaceuticals Inc.

ARC Pharmaceuticals Inc. is developing innovative medical products for the prevention and treatment of surgical adhesions, a major complication in a high proportion of common surgical procedures. Further potential opportunities exist for the technology in the management of arthritis and psoriasis.

Back to Archived News
Looking for...

  © Copyright 2013 Intellectual Property Today
Download Adobe Reader for free